PETER LIBBY, MD
Osteopathic Medicine at Francis St, Boston, MA

2008005, Mar 6, 2008

Mar 12, 2007

11/716996

Uwe Schonbeck - Randolph MA, US
Paul Ridker - Chestnut Hill MA, US
Peter Libby - Boston MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61K 31/19, A61K 31/40, A61K 31/435, A61K 31/44, A61P 9/10, G01N 33/00

514277000, 436086000, 514356000, 514415000, 514460000, 514568000

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

7189518, Mar 13, 2007

Nov 5, 2002

10/288253

Uwe Schönbeck - Randolph MA, US
Paul Ridker - Chestnut Hill MA, US
Peter Libby - Boston MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

G01N 33/53

435 71

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

6812205, Nov 2, 2004

Mar 15, 2001

09/809745

Howard L. Weiner - Brookline MA
Ruth Maron - Brookline MA
Peter Libby - Boston MA

The Brigham Womens Hospital, Inc. - Boston MA

A61K 3800

514 2, 530350, 530300, 435 71, 424 9321, 424 40

Disclosed herein are methods for treating vascular disorders in mammals. The methods involve administering one or more agents selected from the group consisting of a heat shock protein (HSP), a therapeutically effective fragment and a therapeutically effective analog of a heat shock protein in a form suitable for mucosal administration. In some embodiments the heat shock protein of the method is mycobacterial HSP65. In some embodiments the heat shock protein is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The method is of particular value in the treatment of atherosclerosis. Also disclosed are compositions useful for treating vascular disorders in mammals. The compositions include one or more agents selected from the group consisting of heat shock protein, therapeutically effective fragments and therapeutically effective analogs of said heat shock protein in aerosol or oral form. In some embodiments the heat shock protein of the composition is mycobacterial HSP65. In some embodiments the heat shock protein of the method is human HSP60.

6773704, Aug 10, 2004

Oct 26, 2000

09/697613

Harold A. Chapman - San Francisco CA
Guo-Ping Shi - San Francisco CA
Peter Libby - Boston MA
Galina K. Sukhova - Swampscott MA
Daniel I. Simon - Waban MA

The Brigham and Womens Hospital, Inc. - Boston MA

A61K 3816

424 941, 424 946, 424 9465, 530330

The invention provides methods of treating and preventing vascular diseases, by inhibiting cysteine proteases active at sites of vascular injury, particularly cathepsins K and S, by administering cystatin C or TGF-. Cystatin C is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Also provided is a method of diagnosing a patient at risk of, or with, vascular injury by detecting low levels of circulating cystatin C.

2002015, Oct 24, 2002

Mar 13, 2002

10/097683

Miyoung Chun - Belmont MA, US
Uwe Schonbeck - Randolph MA, US
Peter Libby - Boston MA, US

A61K039/395, A61K038/39

424/146100, 514/012000

The present invention is based on the finding that human atheroma-associated endothelial cells (EC), smooth muscle cells (SMC) and macrophages express insterstitial collagenase MMP-8 in vitro, as well as in atherosclerotic lesions in situ. Thus, the invention features methods of modulating the activity or expression of MMP-8 and methods of inhibiting collagen degradation, particularly type I collagen degradation. The invention also features methods of treating or preventing non-neutrophil-mediated inflammatory conditions, in particular cardiovascular disorders such as atherosclerosis; methods of diagnosing and staging such conditions; and methods of evaluating the efficacy of a treatment for such conditions. Finally, the invention features methods of identifying agents that inhibit MMP-8 expression or activity, which can be used for the treatment of non-neutrophil-mediated inflammatory disorders.